RUSNANO
VC Fund
Menlo Park, United States
Rusnano is a joint-stock company aimed at commercializing developments in the nanotechnology industry. It was founded in 2007 and is based in Moscow, Russia.
- Total investments:
- 32
- Last investment:
- Lead investor:
- 50%
- Fund size:
- $463M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries RUSNANO invests in
Stages RUSNANO invests in
Countries RUSNANO invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 7 contacts → | |||
Round size
- Series B
- $2.9M–$20M
- Series E
- $20M–$51M
Investment Focus
Industry
- Manufacturing 6 (19%)
- Electronics 5 (16%)
- Biotechnology 5 (16%)
- Health Care 4 (13%)
- Semiconductor 4 (13%)
Stage
- Funding Round 5 (16%)
- Series E 4 (13%)
- Series B 3 (9%)
- Series F 3 (9%)
- Series D 2 (6%)
Country
- United States 12 (38%)
- Russian Federation 5 (16%)
- Canada 1 (3%)
- Israel 1 (3%)
- Germany 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Anatoly Chubais
CEO
|
CEO | Total investments: 0 | Find email | |
Andrey Kushnarev
Managing Director Investment Management
|
Managing Director Investment Management | Total investments: 0 | Find email | |
Andrey Svinarenko
Deputy Chairman of the Executive Board
|
Deputy Chairman of the Executive Board | Total investments: 0 | Find email | |
Dmitry Akhanov
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
Ish S. Dugal
Investment Director
|
Investment Director | Total investments: 0 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Panacela Labs, Inc. is a joint venture company founded in 2011 by Cleveland BioLabs (Nasdaq:CBLI), a clinical-stage biotechnology company with a focus on oncology and orphan drug development, and Open Joint Stock Company “RUSNANO”, the largest Russian investment company, in collaboration with Roswell Park Cancer Institute, Children’s CancerInstitute of Australia and Cleveland Clinic Foundation. Panacela Labs is 54.6% owned by Cleveland BioLabs. Panacela Labs has residency in the Innovation Center "Skolkovo". | $2.9M / Series B / Dec 24, 2015 | ||
| Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Their proprietary product platform technology combines recent advances in immunobiology with cutting-edge nanotechnology to develop targeted immunomodulatory nanoparticles.Itwas founded in 2008 and is headquartered in Watertown, Massachusetts. | $38M / Series E / Sep 08, 2015 | ||
| Motorica focuses on research and development in modern technologies in medicine and robotics. We produce functional upper limb gadget-prostheses for everyday life. The company works both with individuals and with public and private prosthetic enterprises. Motorica is a resident of Skolkovo Innovation Center, we cooperate with varios internationalcompanies and associations in prostheses field. | $60K / Seed / Sep 01, 2015 | ||
| Crocus Technology SA provides magnetic random access memory products and technologies for the semiconductor and electronic systems industries. It offers its products for use in telecommunication, networking, storage, computing, and handheld applications. | $21M / Series E / Jun 16, 2015 | ||
| KuibyshevAzot is the producer of caprolactam and polyamide-6 in the CIS and Eastern Europe. It is also one of the top-10 Russian nitrogen producers, producing ammonia and a range of nitrogen fertilizers (urea, ammonium nitrate, ammonium sulfate), which account for 5% of total Russian output of fertilizers. | Venture - Series Unknown / Jan 19, 2015 | ||
| Quantenna specializes in providing Wi-Fi solutions. Founded in 2006, Quantenna has demonstrated its leadership in Wi-Fi technologies with many industry firsts in the market. Quantenna continues to innovate with the mission to perfect Wi-Fi by establishing benchmarks for speed, range, efficiency, and reliability. Quantenna takes a multidimensionalapproach, from silicon, a system to software for Wi-Fi networks, and provides solutions for OEMs and service providers worldwide. | $22M / Venture - Series Unknown / Dec 17, 2014 | ||
| Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Their proprietary product platform technology combines recent advances in immunobiology with cutting-edge nanotechnology to develop targeted immunomodulatory nanoparticles.Itwas founded in 2008 and is headquartered in Watertown, Massachusetts. | $20M / Private Equity / Oct 15, 2014 | ||
| SiTime Corporation, an analog semiconductor company, offers MEMS-based silicon timing solutions that replace legacy quartz products. With 85% market share and over 50 million devices shipped, SiTime is driving the $5 Billion timing market’s transition to 100% silicon-based timing.SiTime’s configurable solutions enable customers todifferentiate their products with higher performance, reduced size and better reliability. The rich feature set and flexibility of our solutions allows customers to consolidate their supply-chain, reducing cost of ownership and time to market. By using standard semiconductor processes and high volume plastic packaging, SiTime offers the best availability and shortest lead times in the industry.Top-tier manufacturers are experiencing these benefits and recognize SiTime as: The Smart Timing Choice. | $10M / Series G / Sep 23, 2014 | ||
| At Aquantia, all three elements are present in abundance. Aquantia benefits from team members with a depth of diverse technology development expertise, signal processing innovation and an adherence to lean and agile management practices. Their engineers were at the forefront ofthe Fast Ethernet and Gigabit Ethernet product deployments, and areamong the best in production silicon design.Meet their leadership team, or the board and investors to see their guidance, financial backing and the company they've built. | $16.1M / Series G / Mar 17, 2014 | ||
| Compass-EOS radically changes network routing by shifting it into the age of silicon photonics. The Compass-EOS icPhotonics technology is the world’s first commercial silicon for inter-chip optical interconnect, unleashing the next revolution in routing architectures. Its family of carrier-grade routers is a new breed of scale-out routers, enablingSDN-based, simplified architectures in service provider networks. Since 2006 Compass has attracted top-tier investors ranging from leading venture capital funds to service providers and core routing suppliers. | Series F / Nov 18, 2013 | ||
| See all 32 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does RUSNANO invest in?
RUSNANO invests primarily in Manufacturing, Electronics and Biotechnology startups, most often at Funding Round and Series E stage. Most of the 32 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does RUSNANO invest in?
RUSNANO typically joins rounds of $2.9M–$20M at Series B and $20M–$51M at Series E. These are whole funding-round sizes, not RUSNANO's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds RUSNANO took part in.
How do I contact RUSNANO?
Public channels for RUSNANO include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at RUSNANO?
The team at RUSNANO includes Anatoly Chubais (CEO), Andrey Kushnarev (Managing Director Investment Management) and Andrey Svinarenko (Deputy Chairman of the Executive Board), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
